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A B S T R A C T
Introduction: Use of hydroxychloroquine in patients with coronavirus disease 2019 (COVID-19) was
widespread and uncontrolled until recently. Patients vulnerable to severe COVID-19 are at risk of
hydroxychloroquine interactions with co-morbidities and co-medications contributing to detrimental,
including fatal, adverse treatment effects.
Methods: A retrospective survey was undertaken of health conditions and co-medications of patients
with COVID-19 who were pre-screened for enrolment in a randomized, double-blind, placebo-controlled
hydroxychloroquine multi-centre trial.
Results: The survey involved 305 patients [median age 71 (interquartile range 59–81) years]. The majority
of patients (n = 279, 92%) considered for inclusion in the clinical trial were not eligible, mainly due to
safety concerns caused by health conditions or co-medications. The most common were QT-prolonging
drugs (n = 188, 62%) and haematologic/haemato-oncologic diseases (n = 39, 13%) which prohibited the
administration of hydroxychloroquine. In addition, 165 (54%) patients had health conditions and 167
(55%) patients were on co-medications that did not prohibit the use of hydroxychloroquine but had a risk
of adverse interactions with hydroxychloroquine. The most common were diabetes (n = 86, 28%), renal
insufficiency (n = 69, 23%) and heart failure (n = 58, 19%).
Conclusion: The majority of hospitalized patients with COVID-19 had health conditions or took
co-medications precluding safe treatment with hydroxychloroquine. Therefore, hydroxychloroquine
should be administered with extreme caution in elderly patients with COVID-19, and only in clinical trials.
© 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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The coronavirus disease (COVID-19) pandemic initiated an
rgent search for safe, effective treatments. Repurposing approved
rugs for the treatment of severe acute respiratory syndrome
oronavirus-2 (SARS-CoV-2) infection can save considerable effort,
ime and costs (Krishna et al., 2020). These drugs must be suitable
or use in elderly patients and those with underlying health
onditions as these groups are at particular risk of severe disease
nd complications.
One such drugs is hydroxychloroquine (HCQ), a less toxic and
ore effective derivative of chloroquine (CQ) (Liu et al., 2020; Yao
t al., 2020). With many years of clinical experience, a well-
nderstood safety record, low cost and promising antiviral in-vitro
ctivity, HCQ seemed to be an ideal candidate to manage the
OVID-19 pandemic. As such, it was added to the national
reatment recommendations in China, the USA (Gao and Hu,
020; Lei et al., 2020), France, India, Brazil and other countries. On
 April 2020, the European Medicines Agency stated that HCQ
hould only be used in clinical trials or emergency use programmes
Lei et al., 2020). Until recently, the majority of hospitalized
atients with COVID-19 have been treated with HCQ, including in
he European Union. HCQ has a narrow therapeutic range.
nfortunately, it has been given in varying doses, sometimes
eaching dangerous cumulative levels. Its assumed positive effect
ften led to a very optimistic risk–benefit assessment, even in the
resence of underlying health conditions or concomitant medi-
ations. Concerns about the efficacy and safety of HCQ were soon
aised (Rosenke et al., 2020). Unfavourable clinical courses,
increased adverse effects and higher mortality rates were
discussed in public media, mainly due to the known life-
threatening side effects of CQ and HCQ (Borba et al., 2020). Most
of these side effects (e.g. cardiac arrhythmias) and unfavourable
outcomes occurred in patients with severe COVID-19 and
underlying health conditions (Magagnoli et al., 2020; Rosenberg
et al., 2020), and could have been avoided by more conservative
assessment of potential risks with regard to co-morbidities and
concomitant medications.
While conducting a multi-centre placebo-controlled trial with
HCQ in hospitalized patients with COVID-19, the authors encoun-
tered many obstacles to patient recruitment. Most patients could
not be enrolled in the trial due to co-medications or underlying
health conditions interfering with safe use of HCQ.
As such, the authors decided to undertake a retrospective
survey to determine, in a representative population of hospitalized
patients with COVID-19, the fraction of patients who cannot be
safely treated with HCQ according to the summary of medicinal
product characteristics (SMPC) (Sanofi, 2019). The population
consisted mainly of elderly patients with pre-existing medical
conditions (a group at high risk of severe COVID-19).
Methods
A retrospective evaluation was undertaken of the medical
records of hospitalized patients screened for eligibility for
participation in a randomized, double-blind, HCQ placebo-
controlled multi-centre phase II trial (COV-HCQ trial, EudraCT
no. 2020-001224-33) to assess the safety and efficacy of HCQ
able 1
rial exclusion criteria and medical conditions and concomitant medications unfavourable for use of hydroxychloroquine (HCQ).
n (%)
Patients with COVID-19 considered for inclusion in COV-HCQ study (total) 305 (100)
Patients did not consent 27 (8.9)
Patients included in COV-HCQ study 26 (8.5)
Patients excluded due to health conditions and co-medications 252 (82.6)
Exclusion of patients due the following criteria:a
Intake of QT-prolonging drugsb 188
Treatment in intensive care unit 47
Haemato-oncologic/haematologic diseases 39
Dementia/cognitive impairment 34
Prolonged QT intervalc 13
Retinopathy 7
Intake of experimental COVID-19 treatment 7
Intake of HCQ 5
Acute myocardial infarction 2
Percutaneous endoscopic gastrostomy 2
Bradyarrhythmia 1














Patients with concomitant medications interacting with HCQ 167
Cumulative number of concomitant medications in 167 patients 236OVID-19, coronavirus disease 2019.
a Patients presented with at least one exclusion criterion.
b Cumulative number of QT-prolonging drugs in 188 patients: 375.
c Electrocardiogram and QT were not available for all patients.
d Patients presented with further medical conditions and/or took concomitant medications that warrant increased attention and a careful risk–benefit assessment if HCQ
reatment is considered according to the summary of medicinal product characteristics.
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hospitalized adults with a positive SARS-CoV-2 polymerase chain
reaction (PCR) result were enrolled and received once-daily HCQ
for 7 days (800 mg on day 1, 600 mg/day on days 2–7). These
patients were followed-up until viral clearance and for safety
investigations. The study was conducted in Germany at the
University Hospitals of Tübingen and Hamburg, and local hospitals
in Balingen, Reutlingen and Stuttgart. The COV-HCQ trial and the
retrospective evaluation of medical reports were approved by the
responsible ethics committees in Tübingen, Stuttgart and Ham-
burg. The clinical trial was conducted in accordance with the
Declaration of Helsinki. Written informed consent was obtained
for trial participation, and only de-identified data were collected
for the retrospective analysis.
After the retrospective data evaluation was approved by the
local ethics committees, hospital electronic health records
were searched and de-identified patient data were collected
for hospital stays from 27 March to 28 May 2020. The inclusion
criteria for the retrospective evaluation were: adult, hospital-
ized patients and PCR-confirmed SARS-CoV-2 infection via
nasopharyngeal swab. The following variables were analysed:
age, date of SARS-CoV-2-positive nasopharyngeal swab,
concomitant medication, and underlying health conditions.
Safety margins for the use of HCQ in the COV-HCQ trial were
pre-defined in the trial exclusion criteria, adhering to the SMPC
(Sanofi, 2019), and the recommendations of the Federal
Institute for Drugs and Medical Devices and local ethics
committees. In addition, concomitant medications were
checked for interactions with HCQ using crediblemeds.org,
Medscape drug interaction checker, Liverpool COVID-19 Drug
Interaction and UptoDate. Data analysis was performed using
JMP (SAS). Wilcoxon test and Kruskal–Wallis test were used for
numeric and non-parametric data, respectively.
Results
In total, 305 hospitalized patients with COVID-19 were screened
for eligibility for enrolment in the COV-HCQ trial, and formed part
of this retrospective evaluation. Among the patients, 178 (58%)
were males. Their median age was 71 [interquartile range (IQR)
59–81] years. Female patients [median age 73 (IQR 61–83) years]
were older than male patients [median age 69 (IQR 58–80) years;
P = 0.046].
Of the screened patients, 252 (83%) could not be enrolled in the
COV-HCQ trial due to safety concerns caused by concomitant
medications or various health conditions (Table 1), and 27 (9%) of
screened patients did not give informed consent to participate in
the trial.
The most common reason for exclusion (n = 188, 62%) was
intake of drugs that could prolong the QT interval and cause cardiac
abnormalities, ranging from concomitant intake of one to six QT-
prolonging drugs. Overall, 375 QT-prolonging drug prescriptions
were found as co-medications in this cohort. Other common
reasons for exclusion were intensive care unit treatment (n = 47,
15%), haematologic or haemato-oncologic diseases (n = 39, 13%)
and dementia/cognitive impairment (n = 34, 11%) (Table 1). Five
patients were already receiving HCQ as co-medication.
In addition, 244 (80%) of all patients with COVID-19 had
medical conditions and/or were taking medications that are
not strictly contraindicated but could be unfavourably affected
interfering health conditions or co-medications increased
with age (P < 0.001). In total, 279 (92%) of the screened patients
were not eligible for inclusion in the COV-HCQ trial, mainly due to
safety concerns caused by health conditions or concomitant
medications.
Discussion
This evaluation of medical conditions and co-medications that
preclude safe use of HCQ focused on hospitalized patients with
COVID-19 in Germany. The majority were elderly patients with
multiple underlying health conditions. Dementia and haemato-
logic/haemato-oncological diseases were common co-morbidities
that did not allow trial inclusion. Other co-morbidities such as
diabetes, renal insufficiency and heart failure were additional
reasons to avoid HCQ treatment. These diseases are not only
linked to the age of this cohort – which itself poses a risk of severe
COVID-19 – but are also associated with higher risk of an
unfavourable clinical course of COVID-19 (National Center for
Immunization and Respiratory Diseases, 2020)
Co-medications are another obstacle to safe use of HCQ in
elderly patients with COVID-19. Some adverse effects may not be
clinically significant but can, rarely, have severe consequences.
When HCQ administration is considered, particular attention
should be given to prescribed concomitant QT-prolonging drugs.
Most of the screened patients took at least one QT-prolonging
drug, and half of them took two or more. Cardiac arrhythmias due
to QT prolongation and ventricular tachycardia in patients treated
with CQ led to stopping a trial in Brazil (Borba et al., 2020). When
national treatment recommendations suggested HCQ for the
treatment of COVID-19 during the first pandemic wave, high
numbers of patients were treated with HCQ on a regular basis,
and screening for these known side effects was not always
applied.
Data in a recent meta-analysis including 28 randomized
controlled trials investigating HCQ or CQ as treatment for
COVID-19 showed a combined odds ratio (OR) for all-cause
mortality of 1.11 [95% confidence interval (CI) 1.02–1.20] in the
HCQ-treated patients (Axfors et al., 2021), which indicates a
negative effect of HCQ in the study population. The results were
mainly driven by the RECOVERY trial and the World Health
Organization’s SOLIDARITY trial, which contributed 47% and 19% of
the analysed patients and had ORs for mortality of 1.11 (95% CI
0.96–1.27) and 1.21 (95% CI 0.89–1.63), respectively. In both
trials, very high doses of HCQ were used (800 mg at hours 0 and 6,
400 mg at hour 12 followed by 400 mg every 12 hours for 9 days in
RECOVERY or for 10 days in SOLIDARITY), comparable with twice
the maximum recommended daily dose and reaching levels of
acute intoxication according to the SMPC (RECOVERY Collaborative
Group et al., 2020; Repurposed Antiviral Drugs for Covid-19 —
Interim WHO Solidarity Trial Results, 2021). Both trials included
patients with co-morbidities comparable with those in the COV-
HCQ trial. Recruitment rates of 67% (RECOVERY) and 99%
(SOLIDARITY) were much higher compared with the COV-HCQ
trial (8%). Respectively, mortality rates were 26% and 12%
compared with 3% in the COV-HCQ trial (RECOVERY Collaborative
Group et al., 2020; Repurposed Antiviral Drugs for Covid-19 —
Interim WHO Solidarity Trial Results, 2021). In the meta-analysis, a
subgroup of mainly still unpublished, smaller, well-conducted
placebo-controlled trials showed a trend towards a benefit forby HCQ. Interfering health conditions were identified 267
times in 165 (54%) patients. The most common were diabetes
(n = 86, 28%), renal insufficiency (n = 69, 23%) and heart failure
(n = 58, 19%). Intake of concomitant medications other than QT-
prolonging drugs that can interact with HCQ was found in 167
(55%) patients. The number of trial exclusion criteria, and267HCQ-treated patients with lower mortality (OR 0.88, 95% CI 0.55–
1.41) (Axfors et al., 2021). Careful screening, information and
selection of patients for safe use of HCQ resulted into exclusion of
92% of potential study participants in the COV-HCQ trial, in clear

































J.J. Gabor, A. Kreidenweiss, S. Weber et al. International Journal of Infectious Diseases 106 (2021) 265–268Taken together, uncontrolled and widely applied treatment
ith HCQ in patients with COVID-19 was predictably more harmful
han helpful, particularly in elderly patients. Widespread HCQ
dministration to elderly patients with COVID-19 is not feasible
iven the high rate of underlying health conditions and/or
oncomitant medications. Although the results from randomized,
lacebo-controlled, double-blinded trials with HCQ in patients
ith COVID-19 are not yet available, there are increasing
ndications that HCQ may not be substantially beneficial for these
atients. There may be a niche for justified use in well-assessed
atients, if randomized controlled trials can demonstrate that HCQ
s efficacious and has a beneficial effect in patients with COVID-19.
owever, the administration of HCQ to virtually all hospitalized
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